Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Azilsartan medoxomil (AZL-M) 80 mg demonstrated superior efficacy in office blood pressure reduction, with a 93% probability of being the most effective for systolic BP (blood pressure) and a 90% probability for diastolic BP. In 24-hour ambulatory monitoring, 80 mg AZL-M resulted in a mean systolic reduction of -3.59 mmHg and diastolic reduction of -2.62 mmHg, outperforming lower doses and control.
• The combination of AZL-M with chlorthalidone (AZL-M/CLD) showed greater systolic BP reduction in clinic measurements (-35.1 mmHg) compared to AZL-M with hydrochlorothiazide (-29.5 mmHg). This combination was also effective for chronic kidney disease patients, providing better BP management and adherence.
• For patients with hypertension and diabetes, AZL-M provided superior BP control, while maintaining a safety and tolerability profile similar to that of the control therapy.
• The 80 mg AZL-M group showed an increased incidence of dizziness (OR (odds ratio): 1.56), while the 40 mg AZL-M group reported a higher occurrence of urinary tract infections (OR: 1.82); other adverse events did not differ significantly from the control group.
• The AZL-M and chlorthalidone combination therapy was described as safe and did not raise significant safety concerns, with similar tolerability to other antihypertensive therapies.
• There is no population types or subgroups information available in the reviewed studies.